Summary

Global Neoantigen Targeted Therapies Market was valued at USD 1.88 billion in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 8.34% through 2030. Neoantigen Targeted Therapies are a cutting-edge approach in cancer treatment that harnesses the power of the immune system to specifically recognize and attack cancer cells. These therapies are designed to target neoantigens, which are unique protein fragments found on the surface of cancer cells because of mutations in the tumor's DNA. For instance, according to a study published by the Indian Journal of Medical Research in December 2022, the estimated number of new cancer cases in India for 2022 was 14,61,427. The report highlights the growing cancer burden in the country, emphasizing the need for enhanced awareness, early detection, and improved treatment strategies to address the rising incidence. Neoantigens are distinct from normal, healthy cell proteins, making them ideal targets for immune recognition and attack. Neoantigen therapies are highly personalized. Once neoantigens are identified, the patient's immune system is trained to recognize these specific neoantigens as foreign invaders. This often involves creating a customized vaccine or adoptive cell therapy tailored to the patient's unique neoantigen profile. Neoantigen therapies can be used in combination with checkpoint inhibitors, another type of immunotherapy. Checkpoint inhibitors release the brakes on the immune system, allowing it to mount a stronger response against cancer cells, including those targeted by neoantigens.
The growing availability and affordability of genomic sequencing technologies have enabled the identification of neoantigens more accurately and quickly, facilitating the development of personalized therapies. Regulatory agencies like the FDA and EMA have shown willingness to support the development and approval of neoantigen therapies, streamlining the path to market for these treatments. Patients and healthcare providers are increasingly seeking precision therapies that specifically target cancer cells. Neoantigen therapies offer the potential for more effective and less toxic treatments. Researchers are exploring the synergistic effects of combining neoantigen therapies with other treatment modalities, such as chemotherapy and radiation therapy, to enhance treatment outcomes. The aging population is at higher risk of developing cancer. As the global population ages, the demand for innovative cancer treatments, including neoantigen therapies, is expected to rise.
Key Market Drivers
Advancements in Genomic Testing
Next-generation sequencing technologies have revolutionized the field of genomics. NGS allows for the rapid and cost-effective sequencing of large stretches of DNA. It has enabled the sequencing of entire genomes, transcriptomes, and epigenomes with unprecedented speed and affordability. For instance, a study published in PNAS in September 2022 reported that researchers developed an antibody-based therapy that successfully eliminated circulating tumor cells (CTCs) in breast cancer mouse models. This breakthrough highlights the potential of targeted immunotherapy in preventing cancer metastasis, offering hope for improved treatment strategies and better outcomes for breast cancer patients in the future. High-throughput sequencing platforms can simultaneously process numerous DNA or RNA samples, allowing for large-scale studies and population-scale genomic research. This capability has accelerated the discovery of genetic variants associated with diseases and traits. Traditional short-read sequencing methods have limitations in resolving complex genomic regions. Long-read sequencing technologies, like Pacific Biosciences (PacBio) and Oxford Nanopore, can generate much longer sequencing reads, aiding in the assembly of complete genomes and the identification of structural variations. Single-cell sequencing technologies enable the analysis of individual cells within a tissue or organism. This approach provides insights into cellular heterogeneity, cell types, and gene expression at a single-cell resolution, advancing our understanding of complex biological systems. Genomic sequencing has been instrumental in cancer research and precision oncology. It allows for the identification of driver mutations, assessment of tumor heterogeneity, and the development of targeted therapies tailored to a patient's genetic profile.
Key Market Challenges
Identification of Relevant Neoantigens
Tumors are often genetically heterogeneous, meaning they contain a mix of different cell types with various mutations. Identifying the specific neoantigens that are present across all tumor cells can be challenging. Neoantigen prediction relies on computational algorithms to predict potential neoantigens based on DNA sequencing data. These algorithms are continually improving, but false positives and false negatives are still common, leading to uncertainty in selecting the most relevant neoantigens. Predicted neoantigens must be experimentally validated to confirm their presentation on cancer cells and their immunogenicity. This validation process can be time-consuming and resource intensive. Each patient's tumor has a unique set of neoantigens, and these can vary greatly from one patient to another. Identifying relevant neoantigens requires a personalized approach for each patient, which can be logistically challenging. Some neoantigens may be present at very low frequencies within a tumor, making them difficult to detect and target effectively. Tumors can evolve over time, leading to changes in their neoantigen landscape. This requires ongoing monitoring and adaptation of neoantigen-targeted therapies. Cancer cells may develop mechanisms to evade the immune system, including downregulating the presentation of neoantigens. This immune evasion can hinder the effectiveness of neoantigen-targeted therapies.
Key Market Trends
Immunotherapy Dominance
Immunotherapy has gained prominence as a leading approach in cancer treatment. It harnesses the body's immune system to target and destroy cancer cells. Neoantigen-targeted therapies are a subset of immunotherapy that focuses on training the immune system to recognize and attack cancer-specific neoantigens. Immunotherapy, including neoantigen-targeted therapies, aligns with the principles of precision medicine. These therapies are tailored to the individual genetic and immunological profiles of each patient, aiming to maximize treatment efficacy while minimizing side effects. Neoantigen-targeted therapies often complement the use of checkpoint inhibitors, another class of immunotherapies. Checkpoint inhibitors release the brakes on the immune system, allowing it to attack cancer cells more effectively. Neoantigens can serve as specific targets for the immune system to recognize in combination with checkpoint inhibitors. Neoantigen-targeted therapies aim to enhance the immune system's response against cancer cells by targeting neoantigens, which are unique to the tumor. This can lead to a more focused and potent immune response compared to traditional treatments. Positive outcomes and clinical successes in immunotherapy trials, including neoantigen therapies, have fueled interest and investment in this field. Patients who have experienced durable responses are advocating for and raising awareness of these treatments. The pharmaceutical and biotechnology industries have invested heavily in the research and development of immunotherapies, including neoantigen-based approaches. This investment has led to a growing pipeline of potential therapies.
Key Market Players
• BioNtech SE
• Gritstone Bio, Inc.
• Genocea Biosciences Inc.
• Moderna Inc
• Agenus Inc.
• Immatics NV
• Advaxis Inc
• Precision Biologics
• Gilead Sciences, Inc.
• Cellular Biomedicine Group Inc.
• Achillies Therapeutics Plc.
• Merck & Co Inc
Report Scope:
In this report, the Global Neoantigen Targeted Therapies Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
• Neoantigen Targeted Therapies Market, By Target Disease Indication:
o Bone Cancer
o Colorectal Cancer
o Gynecological Cancer
o Non-Small Cell Lung Cancer
o Renal Cell Carcinoma
• Neoantigen Targeted Therapies Market, By Neoantigens Type:
o Off-the-Shelf Neoantigens
o Personalized Neoantigens
• Neoantigen Targeted Therapies Market, By Immunotherapy Type:
o Dendritic Cell Vaccines
o DNA / RNA-Based Vaccines
o Protein / Peptide-based Vaccines
o TIL-Based Therapies
• Neoantigen Targeted Therapies Market, By Route of Administration:
o Intradermal
o Intravenous
o Subcutaneous
• Neoantigen Targeted Therapies Market, By region:
o North America
§ United States
§ Canada
§ Mexico
o Asia-Pacific
§ China
§ India
§ South Korea
§ Australia
§ Japan
o Europe
§ Germany
§ France
§ United Kingdom
§ Spain
§ Italy
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Neoantigen Targeted Therapies Market.
Available Customizations:
Global Neoantigen Targeted Therapies Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
• Detailed analysis and profiling of additional market players (up to five).

ページTOPに戻る

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Applications
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Impact of COVID-19 on Global Neoantigen Targeted Therapies Market
5. Voice of Customer
6. Global Neoantigen Targeted Therapies Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Target Disease Indication (Bone Cancer, Colorectal Cancer, Gynecological Cancer, Non-Small Cell Lung Cancer, Renal Cell Carcinoma)
6.2.2. By Neoantigens Type (Off-the-Shelf Neoantigens, Personalized Neoantigens)
6.2.3. By Route of Administration (Intradermal, Intravenous, Subcutaneous)
6.2.4. By Immunotherapy Type (Dendritic Cell Vaccines, DNA / RNA-Based Vaccines, Protein / Peptide-based Vaccines, TIL-Based Therapies)
6.2.5. By Region
6.2.6. By Company (2024)
6.3. Market Map
7. Asia Pacific Neoantigen Targeted Therapies Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Target Disease Indication
7.2.2. By Neoantigens Type
7.2.3. By Route of Administration
7.2.4. By Immunotherapy Type
7.2.5. By Country
7.3. Asia Pacific: Country Analysis
7.3.1. China Neoantigen Targeted Therapies Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Target Disease Indication
7.3.1.2.2. By Neoantigens Type
7.3.1.2.3. By Route of Administration
7.3.1.2.4. By Immunotherapy Type
7.3.2. India Neoantigen Targeted Therapies Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Target Disease Indication
7.3.2.2.2. By Neoantigens Type
7.3.2.2.3. By Route of Administration
7.3.2.2.4. By Immunotherapy Type
7.3.3. Australia Neoantigen Targeted Therapies Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Target Disease Indication
7.3.3.2.2. By Neoantigens Type
7.3.3.2.3. By Route of Administration
7.3.3.2.4. By Immunotherapy Type
7.3.4. Japan Neoantigen Targeted Therapies Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Target Disease Indication
7.3.4.2.2. By Neoantigens Type
7.3.4.2.3. By Route of Administration
7.3.4.2.4. By Immunotherapy Type
7.3.5. South Korea Neoantigen Targeted Therapies Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Target Disease Indication
7.3.5.2.2. By Neoantigens Type
7.3.5.2.3. By Route of Administration
7.3.5.2.4. By Immunotherapy Type
8. Europe Neoantigen Targeted Therapies Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Target Disease Indication
8.2.2. By Neoantigens Type
8.2.3. By Route of Administration
8.2.4. By Immunotherapy Type
8.2.5. By Country
8.3. Europe: Country Analysis
8.3.1. France Neoantigen Targeted Therapies Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Target Disease Indication
8.3.1.2.2. By Neoantigens Type
8.3.1.2.3. By Route of Administration
8.3.1.2.4. By Immunotherapy Type
8.3.2. Germany Neoantigen Targeted Therapies Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Target Disease Indication
8.3.2.2.2. By Neoantigens Type
8.3.2.2.3. By Route of Administration
8.3.2.2.4. By Immunotherapy Type
8.3.3. Spain Neoantigen Targeted Therapies Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Target Disease Indication
8.3.3.2.2. By Neoantigens Type
8.3.3.2.3. By Route of Administration
8.3.3.2.4. By Immunotherapy Type
8.3.4. Italy Neoantigen Targeted Therapies Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Target Disease Indication
8.3.4.2.2. By Neoantigens Type
8.3.4.2.3. By Route of Administration
8.3.4.2.4. By Immunotherapy Type
8.3.5. United Kingdom Neoantigen Targeted Therapies Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Target Disease Indication
8.3.5.2.2. By Neoantigens Type
8.3.5.2.3. By Route of Administration
8.3.5.2.4. By Immunotherapy Type
9. North America Neoantigen Targeted Therapies Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Target Disease Indication
9.2.2. By Neoantigens Type
9.2.3. By Route of Administration
9.2.4. By Immunotherapy Type
9.2.5. By Country
9.3. North America: Country Analysis
9.3.1. United States Neoantigen Targeted Therapies Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Target Disease Indication
9.3.1.2.2. By Neoantigens Type
9.3.1.2.3. By Route of Administration
9.3.1.2.4. By Immunotherapy Type
9.3.2. Mexico Neoantigen Targeted Therapies Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Target Disease Indication
9.3.2.2.2. By Neoantigens Type
9.3.2.2.3. By Route of Administration
9.3.2.2.4. By Immunotherapy Type
9.3.3. Canada Neoantigen Targeted Therapies Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Target Disease Indication
9.3.3.2.2. By Neoantigens Type
9.3.3.2.3. By Route of Administration
9.3.3.2.4. By Immunotherapy Type
10. South America Neoantigen Targeted Therapies Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Target Disease Indication
10.2.2. By Neoantigens Type
10.2.3. By Route of Administration
10.2.4. By Immunotherapy Type
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Neoantigen Targeted Therapies Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Target Disease Indication
10.3.1.2.2. By Neoantigens Type
10.3.1.2.3. By Route of Administration
10.3.1.2.4. By Immunotherapy Type
10.3.2. Argentina Neoantigen Targeted Therapies Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Target Disease Indication
10.3.2.2.2. By Neoantigens Type
10.3.2.2.3. By Route of Administration
10.3.2.2.4. By Immunotherapy Type
10.3.3. Colombia Neoantigen Targeted Therapies Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Target Disease Indication
10.3.3.2.2. By Neoantigens Type
10.3.3.2.3. By Route of Administration
10.3.3.2.4. By Immunotherapy Type
11. Middle East and Africa Neoantigen Targeted Therapies Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Target Disease Indication
11.2.2. By Neoantigens Type
11.2.3. By Route of Administration
11.2.4. By Immunotherapy Type
11.2.5. By Country
11.3. MEA: Country Analysis
11.3.1. South Africa Neoantigen Targeted Therapies Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Target Disease Indication
11.3.1.2.2. By Neoantigens Type
11.3.1.2.3. By Route of Administration
11.3.1.2.4. By Immunotherapy Type
11.3.2. Saudi Arabia Neoantigen Targeted Therapies Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Target Disease Indication
11.3.2.2.2. By Neoantigens Type
11.3.2.2.3. By Route of Administration
11.3.2.2.4. By Immunotherapy Type
11.3.3. UAE Neoantigen Targeted Therapies Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Target Disease Indication
11.3.3.2.2. By Neoantigens Type
11.3.3.2.3. By Route of Administration
11.3.3.2.4. By Immunotherapy Type
12. Market Dynamics
12.1. Drivers
12.2. Challenges
13. Market Trends & Developments
13.1. Recent Developments
13.2. Product Launches
13.3. Mergers & Acquisitions
14. Global Neoantigen Targeted Therapies Market: SWOT Analysis
15. Porter’s Five Forces Analysis
15.1. Competition in the Industry
15.2. Potential of New Entrants
15.3. Power of Suppliers
15.4. Power of Customers
15.5. Threat of Substitute Product
16. PESTLE Analysis
17. Competitive Landscape
17.1. BioNtech SE
17.1.1. Business Overview
17.1.2. Company Snapshot
17.1.3. Products & Services
17.1.4. Financials (In case of listed companies)
17.1.5. Recent Developments
17.2. Gritstone Bio, Inc.
17.3. Genocea Biosciences Inc
17.4. Moderna Inc.
17.5. Agenus Inc.
17.6. Immatics N.V.
17.7. Advaxis Inc.
17.8. Precision Biologics
17.9. Gilead Sciences, Inc.
17.10. Cellular Biomedicine Group, Inc.
17.11. Achillies Therapeutics Plc.
17.12. Merck & Co, Inc.
18. Strategic Recommendations
19. About Us & Disclaimer